Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS r...

Full description

Bibliographic Details
Main Authors: Wenqi Zhang, Chen Huang, Ruixia Liu, Huichao Zhang, Weijing Li, Shaoning Yin, Lianjing Wang, Wei Liu, Lihong Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
scnsl
CD19 CAR-T cell therapy
BTK inhibitor
PD-1 antibody
zanubrutinib
tislelizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.983934/full
Description
Summary:Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton’s tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL.Clinical Trial RegistrationClinicalTrials.gov number, NCT04666168.
ISSN:1664-3224

Similar Items